SCHEMBL3780644

SCHEMBL3780644

COc1ccc(CC(=O)N2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)c(OC)c1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
KDM4E B2RXH2 1/20 0.55
GAA P10253 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
KMT2A Q03164 5/20 0.50
TSHR P16473 1/20 0.50
RAB9A P51151 1/20 0.50
OXTR P30559 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.49
MEN1 O00255 2/20 0.47
KDM2B Q8NHM5 3/20 0.47
CBX7 O95931 1/20 0.46
CDYL2 Q8N8U2 1/20 0.46
CDYL Q9Y232 1/20 0.46
HRH3 Q9Y5N1 1/20 0.45
SIGMAR1 Q99720 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3774233 0.92 RAB9A (0.57) ALDH1A1KDM4EGAATDP1KMT2A
SCHEMBL3773641 0.86 KMT2A (0.64) ALDH1A1KDM4ETDP1KMT2ATSHR
SCHEMBL3769405 0.86 KDM2B (0.54) ALDH1A1KDM4EGAAKMT2ATSHR
SCHEMBL3777237 0.84 SMN1; SMN2 (0.64) ALDH1A1KDM4EGAAKMT2ATSHR
SCHEMBL3772205 0.84 ALDH1A1 (0.50) ALDH1A1KDM4EKMT2ATSHRRAB9A
SCHEMBL3770901 0.84 ALDH1A1 (0.53) ALDH1A1KDM4EGAATDP1KMT2A
SCHEMBL3773681 0.83 KDM4E (0.55) ALDH1A1KDM4ETDP1KMT2ATSHR
SCHEMBL3773990 0.83 ALDH1A1 (0.54) ALDH1A1KDM4EGAATDP1KMT2A
SCHEMBL3773282 0.82 CCR3 (0.43) ALDH1A1KDM4EKMT2ATSHRRAB9A
SCHEMBL3770061 0.82 SIGMAR1 (0.63) ALDH1A1KDM4EGAATDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885KDM4E 534/4885GAA 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.